Autres langues NH TherAguix SAS

Actions

Marché Fermé - Euronext Paris Autres places de cotation 02:34:17 22/10/2021			Varia. 5j.	Varia. 1 janv.
0,01 ^EUR	-.--%		-.--%	-.--%

NH TherAguix SAS : announces the publication of promising preclinical results of AGuIX® in combination with targeted radioligand therapies (TRT)	19/12
NH TherAguix SAS : appoints Vincent Carrère as Chief Executive Officer	12/09/23
NH TherAguix SAS : announces communications to be presented at the AAPM meeting by Harvard Medical Schools collaborators	21/07/23
NH TherAguix SAS : announces the arrival of Aurélien Meyzaud as Head of Intellectual Property and Business Intelligence	13/01/23
NH TherAguix SAS : announces the thesis defense of Dr. Paul Rocchi as the first NHT-funded PhD student	09/11/22
NH TherAguix SAS and Carbogen AMCIS AG Announce the Release of New Batch of AGuIX Drug Product for Clinical Trials	28/10/21

Aucun résultat pour cette recherche